Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 2/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.30 |
| ▸ | NOS1 | P29475 | 2/20 | 0.30 |
| ▸ | NOS2 | P35228 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21243702 | 0.72 | GPR55 (0.39) | — | |
| SCHEMBL26125109 | 0.68 | IDO1 (0.43) | NPSR1 | |
| SCHEMBL16223030 | 0.66 | LMNA (0.56) | LMNATSHR | |
| SCHEMBL4908543 | 0.66 | ESR1 (0.41) | PDE3BPDE3A | |
| SCHEMBL4246815 | 0.66 | PTGS2 (0.47) | — | |
| SCHEMBL1335905 | 0.66 | XDH (0.39) | LMNA | |
| SCHEMBL1335295 | 0.66 | RAB9A (0.44) | LMNA | |
| SCHEMBL27790305 | 0.65 | GP6 (0.39) | PTPN1PTPN2 | |
| SCHEMBL1335198 | 0.65 | PTGS2 (0.45) | LMNABLMNPSR1 | |
| SCHEMBL27450956 | 0.65 | LMNA (0.34) | LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202782-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2012-08-09 | — | — | US | disclosed |
| US-20120202782-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2012-08-09 | — | — | US | disclosed |
| US-20120202782-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2012-08-09 | — | — | US | disclosed |
| US-8178526-B2 | Compounds and compositions as ITPKb inhibitors | IRM LLC (BM) | 2012-05-15 | — | — | US | disclosed |
| US-8178526-B2 | Compounds and compositions as ITPKb inhibitors | IRM LLC (BM) | 2012-05-15 | — | — | US | disclosed |
| US-8178526-B2 | Compounds and compositions as ITPKb inhibitors | IRM LLC (BM) | 2012-05-15 | — | — | US | disclosed |
| EP-2167498-B1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2010-09-15 | — | — | EP | disclosed |
| US-20100184748-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2010-07-22 | — | — | US | disclosed |
| US-20100184748-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2010-07-22 | — | — | US | disclosed |
| US-20100184748-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2010-07-22 | — | — | US | disclosed |
| CN-101743243-A | Compounds and compositions as ITPKB inhibitors | IRM LLC | 2010-06-16 | — | — | CN | disclosed |
| EP-2167498-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008157210-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008157210-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202782-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IP6K1, IP6K2, IP6K3 | PDE3B 989/4885PDE3A 1440/4885PTPN1 653/4885 |
| US-20100184748-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IP6K1, IP6K3, IP6K2 | PDE3B 527/4885PDE3A 930/4885PTPN1 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.